Johnson & Johnson (NYSE: JNJ) has a higher price-to-earnings ratio of 17.25x compared to its average ratio, The 36-month beta value for JNJ is at 0.40. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 13 as “hold,” and 0 as “sell.”
The public float for JNJ is 2.40B, and currently, shorts hold a 0.95% of that float. The average trading volume for JNJ on June 02, 2025 was 9.39M shares.
JNJ) stock’s latest price update
Johnson & Johnson (NYSE: JNJ) has experienced a rise in its stock price by 1.06 compared to its previous closing price of 153.58. However, the company has seen a gain of 1.70% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-30 that Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company’s structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major drugs like Darzalex Faspro.
JNJ’s Market Performance
JNJ’s stock has risen by 1.70% in the past week, with a monthly drop of -0.70% and a quarterly drop of -5.94%. The volatility ratio for the week is 0.70% while the volatility levels for the last 30 days are 1.31% for Johnson & Johnson. The simple moving average for the past 20 days is 1.38% for JNJ’s stock, with a -0.89% simple moving average for the past 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with Leerink Partners repeating the rating for JNJ by listing it as a “Market Perform.” The predicted price for JNJ in the upcoming period, according to Leerink Partners is $153 based on the research report published on May 13, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $166. The rating they have provided for JNJ stocks is “Neutral” according to the report published on December 10th, 2024.
Wolfe Research gave a rating of “Outperform” to JNJ, setting the target price at $190 in the report published on November 15th of the previous year.
JNJ Trading at -0.02% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.69% of loss for the given period.
Volatility was left at 1.31%, however, over the last 30 days, the volatility rate increased by 0.70%, as shares surge +0.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.77% lower at present.
During the last 5 trading sessions, JNJ rose by +1.70%, which changed the moving average for the period of 200-days by -2.92% in comparison to the 20-day moving average, which settled at $153.10. In addition, Johnson & Johnson saw 7.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Decker Robert J, who sale 6,999 shares at the price of $165.88 back on Feb 25 ’25. After this action, Decker Robert J now owns 21,001 shares of Johnson & Johnson, valued at $1,160,994 using the latest closing price.
Decker Robert J, the Officer of Johnson & Johnson, proposed sale 6,999 shares at $165.88 during a trade that took place back on Feb 25 ’25, which means that Decker Robert J is holding shares at $1,161,010 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.68 for the gross margin
The net margin for Johnson & Johnson stands at 0.24. The total capital return value is set at 0.16. Equity return is now at value 29.45, with 11.93 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.47. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is 27.46.
Currently, EBITDA for the company is 24.78 billion with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 4.33. The receivables turnover for the company is 5.58for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In conclusion, Johnson & Johnson (JNJ) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
